Citi cuts Novo Nordisk stock target from DKK 310.00 to DKK 296.00
Published on 10/13/2026 at 14:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Citi analyst Graham Parry lowered Novo Nordisk's target from DKK 310.00 to DKK 296.00 on October 9, 2026, while keeping a Neutral rating, according to Markets Insider. Against the DKK 258.55 Copenhagen quote on October 13, 2026, the revised target lies 14.48 percent higher. At Lang & Schwarz, Novo Nordisk was trading at EUR 34.59 on October 13, 2026 at 2:04 p.m. CEST.
Results date sets the next checkpoint
Novo Nordisk's investor calendar lists November 4, 2026, at 7:30 a.m. CEST for the release of results covering the first three quarters of 2026, according to Novo Nordisk. That date is the next scheduled earnings event after the company's second-quarter report announced on August 4, 2026.
Price remains close to the yearly floor
The Copenhagen quote of DKK 258.55 stood inside a 52-week range of DKK 224.30 to DKK 410.00 on October 13, 2026. The price was 15.28 percent above the range low and 36.94 percent below the high, calculated from the same DKK values.
The finance profile put Novo Nordisk's market capitalization at DKK 1.1 trillion and its P/E ratio at 9.87 on October 13, 2026. The listing information identifies Copenhagen as the home exchange and also shows Xetra as a secondary listing, according to Investing.com.
Euro quote and investor reference
The Lang & Schwarz euro quote was EUR 34.59 at 2:04 p.m. CEST on October 13, 2026. The Copenhagen price provides a separate home-market view at DKK 258.55 at 2:08 p.m. CEST, while the Citi target remains DKK 296.00.
The further course of trading is shown by the continuously updated real-time quote of Novo Nordisk stock.
Novo Nordisk stock facts
- Company: Novo Nordisk A/S
- ISIN: DK0062498333
- Ticker: NOVO-B.CO
- Primary exchange: Nasdaq Copenhagen
- Price Lang & Schwarz (as of October 13, 2026, 2:04 p.m. CEST): EUR 34.59
- Market capitalization: DKK 1.1 trillion (as of October 13, 2026)
- 52-week range: DKK 224.30-410.00 (as of October 13, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - General
Market context: Current market reports.
